Kiniksa Pharmaceuticals (KNSA) to Release Quarterly Earnings on Tuesday

Kiniksa Pharmaceuticals (NASDAQ:KNSA) is scheduled to be announcing its earnings results before the market opens on Tuesday, October 29th. Analysts expect the company to announce earnings of ($0.01) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Kiniksa Pharmaceuticals Price Performance

Shares of KNSA opened at $27.44 on Friday. The firm has a market cap of $1.95 billion, a P/E ratio of 249.45 and a beta of 0.33. The stock has a 50 day simple moving average of $25.68 and a two-hundred day simple moving average of $22.27. Kiniksa Pharmaceuticals has a 1 year low of $14.12 and a 1 year high of $27.92.

Analysts Set New Price Targets

KNSA has been the subject of several recent research reports. Wedbush boosted their price objective on Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the company an “outperform” rating in a research report on Tuesday, July 23rd. Jefferies Financial Group initiated coverage on Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They issued a “buy” rating and a $40.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $33.60.

Insider Activity at Kiniksa Pharmaceuticals

In related news, COO Eben Tessari sold 17,500 shares of the company’s stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $24.99, for a total transaction of $437,325.00. Following the completion of the transaction, the chief operating officer now owns 116,975 shares in the company, valued at $2,923,205.25. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, insider John F. Paolini sold 60,692 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total transaction of $1,585,275.04. Following the completion of the transaction, the insider now owns 52,038 shares in the company, valued at $1,359,232.56. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Eben Tessari sold 17,500 shares of the company’s stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $24.99, for a total value of $437,325.00. Following the completion of the sale, the chief operating officer now directly owns 116,975 shares in the company, valued at approximately $2,923,205.25. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 112,692 shares of company stock worth $2,950,315 over the last quarter. 54.57% of the stock is owned by corporate insiders.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.